Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Dietary Supplement: Folic Acid
Dietary Supplement: Vitamin B12
Drug: dexamethasone

First Posted Date: 2008-02-07

Last Posted Date: 2010-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 111

Registration Number: NCT00609518

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

Phase 4

Completed

Conditions: Attention Deficit Hyperactivity Disorder
Dyslexia

Interventions: Drug: Placebo
Drug: Atomoxetine

First Posted Date: 2008-02-06

Last Posted Date: 2011-12-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 209

Registration Number: NCT00607919

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States

A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: Best Supportive Care

First Posted Date: 2008-02-01

Last Posted Date: 2011-12-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 106

Registration Number: NCT00606021

Locations: 🇸🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Riyadh, Saudi Arabia

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Phase 3

Completed

Conditions: Sepsis

Interventions: Drug: Placebo
Drug: Drotrecogin alfa (activated)

First Posted Date: 2008-01-30

Last Posted Date: 2012-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1696

Registration Number: NCT00604214

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: LY450139

First Posted Date: 2008-01-15

Last Posted Date: 2015-03-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1537

Registration Number: NCT00594568

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stoke-On-Trent, United Kingdom

Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

Phase 2

Completed

Conditions: Recurrent Glioblastoma

Interventions: Drug: enzastaurin
Drug: bevacizumab
Drug: Enzyme-inducing antiepileptic drugs (EIAED)
Drug: Non-enzyme inducing antiepileptic drugs (NEIAED)

First Posted Date: 2008-01-04

Last Posted Date: 2020-09-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 81

Registration Number: NCT00586508

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

Phase 3

Completed

Conditions: Osteoporosis

First Posted Date: 2007-12-20

Last Posted Date: 2009-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 200

Registration Number: NCT00577863

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beckley, West Virginia, United States

Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients

Phase 3

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: Somatropin

First Posted Date: 2007-12-10

Last Posted Date: 2007-12-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 112

Registration Number: NCT00570011

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Atomoxetine hydrochloride

First Posted Date: 2007-12-06

Last Posted Date: 2010-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 153

Registration Number: NCT00568685

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

An Open Label Study of Severe Sepsis in Adults

Phase 4

Completed

Conditions: Severe Sepsis

Interventions: Drug: drotrecogin alfa (activated)

First Posted Date: 2007-12-06

Last Posted Date: 2007-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 130

Registration Number: NCT00568893

Locations: 🇧🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilrijk, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy